Belgium· BE-AMP-SAM053313-00
Tebrazid 500 mg
A pyrazinamide product containing pyrazinamide, registered in Belgium by BePharBel Manufacturing. The same ATC class is registered in 14 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Pyrazinamide is registered in 14 of 19 countries.
Countries holding a registration under ATC J04AK01 (pyrazinamide), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 8 of them publish a price we can compare per daily dose
Pyrazinamide · ATC J04AK01
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of pyrazinamide costs, country by country.
Normalised to the WHO defined daily dose (1.5 g), the median price runs from $0.61 in France to $3.20 in Switzerland — a ×5.2 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Pyrazinamide · price per daily dose (1.5 g)
USD · FX 28 Sept 2026
- CH Switzerland$3.20
- FR France$0.61
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Pyrazinamide
- Manufacturer
- BePharBel Manufacturing
- Country
- Belgium (BE)
- ATC code
- J04AK01
- ATC class
- Pyrazinamide
- Defined daily dose
- 1.5 g, O
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
1 priced- be_apb0085910EUR 34.87
- be_apb0718700
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
81 interactions on record for pyrazinamide.
Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Pyrazinamide · interactions on record
81 records
- 4 severe
- 19 moderate
- 54 info
Most severe, free to view
- LeflunomidL04AA13severe
- TeriflunomidL04AA31severe
- LeflunomideL04AK01severe
- TeriflunomideL04AK02severe
4 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Pyrazinamide in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomPyrazinamide 1.25g/5ml oral solutionSpecial Order
- United StatespyrazinamideHikma Pharmaceuticals USA Inc
- SwitzerlandPyrazinamide Labatec 400 mg, comprimésLabatec Pharma SA
- GermanyPyrafatEsteve Pharmaceuticals Gmbh
- NorwayPyrazinamid SASykehusapotekene HF
- FinlandPyrazinamidPharmacal Oy Ab
- FrancePIRILENE 500 mg, compriméSANOFI WINTHROP INDUSTRIE
- CzechiaPYRAZINAMID KRKA
Authorised across Europe · EMA
The same active substance is authorised in 19 EEA countries. Names it is sold under:
- Austria · Pyrafat
- Bulgaria · Пиразинамид Крка
- Germany · Pyrafat, Pyrazinamid Jenapharm
- Denmark · Pyrazinamid Sad
- Spain · Pirazinamida Prodes
- Finland · Tisamid
- France · Pirilene
- United Kingdom (Northern Ireland) · Pyrazinamide Morningside Healthcare
- Greece · Pyrazinamide Genepharm
- Croatia · Pyrazinamid Krka
- Lithuania · Pyrafat, Pyrazinamide Krka
- Luxembourg · Tebrazid
- Latvia · Pyrazinamide Olpha
- Malta · Pyrazinamide Morningside Healthcare
- Netherlands · Pyrazinamide Cf
- Poland · Pyrazinamid Farmapol
- Portugal · Pramide
- Romania · Pirazinamida Atb
- Slovenia · Pirazinamid Krka
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/6131cc17-c60a-4c9f-bf20-b065079aae4c GET /v1/drugs/6131cc17-c60a-4c9f-bf20-b065079aae4c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tablet",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Tebrazid 500 mg",
"name_fr": "Tebrazid 500 mg",
"name_nl": "Tebrazid 500 mg",
"amp_code": "SAM053313-00",
"strengths": [
"500.0000",
"500.0000",
"10.0000"
],
"pack_count": 4,
"substances": [
"Pyrazinamide",
"Sodium Starch Glycolate"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Pyrazinamide",
"authorisation_numbers": [
"BE053313"
]
}See everything about pyrazinamide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.